BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Linden Bioscience Introduces Strategic Proteomic Services


10/19/2005 5:09:22 PM

WOBURN, Mass.--(BUSINESS WIRE)--Dec. 2, 2003--Linden Bioscience today introduced a new protein identification service designed to provide research organizations with access to state-of-the-art informatics systems, novel scientific techniques, and project-dedicated scientists. Strategic Proteomic Services(TM) leverages Linden Bioscience's multi-million dollar proteomics program investment - in support of the company's integrated biomarker discover platform - over the past year.

The service features state-of-the-art analysis coupled with rapid, comprehensive protein identification through tightly-integrated informatics systems and processes. At the heart of the service are the ABI 4700 Proteomics Analyzer (MALDI TOF/TOF(TM)) and QSTAR® XL (LC/MS/MS) mass spectrometer systems. As part of the service, Linden Bioscience is providing direct access to project-dedicated company researchers. The company's scientists have optimized methods to maximize recovery from silver-stained protein gel samples (which contain only trace amounts of protein), as well as Coomassie and SYPRO Ruby techniques, while minimizing contamination. The service leverages the company's bioinformatics systems and resources to provide the annotation for detected proteins. Optionally, organizations can have Linden Bioscience researchers run 1D and 2D gel electrophoresis with or without mass spectrometry services.

Strategic Proteomic Services also features Functional Tissue Microdissection (FTM), a novel method developed by Linden Bioscience partner, TransMedix, for gathering single cells or small collections of cells. When coupled with FTM, Strategic Proteomic Services allow researchers to utilize highly-purified, disease-specific tissues in identifying potentially novel biomarkers or targets expressed in the particular disease. FTM relies on tumor and normal tissue to be collected at the time of the surgery so that it can be frozen in liquid nitrogen and stored until dissected. This process maximizes the recovery of intact protein and RNA while preserving histology for the technique. Recent publications have demonstrated the value of microdissection techniques, such as FTM, on the quantitation of genes expressed in diseased versus normal tissues.

With its Strategic Proteomic Services, Linden Bioscience is primarily targeting non-commercial research organizations, those that have intensive, yet periodic, protein profiling needs. For such organizations, it is more attractive to outsource than make a steep investment in high-end proteomics systems. Overall, the service is for organizations studying protein structure and function in normal and diseased tissues to shed light on potential drug targets and biomarkers.

"We have been building up our proteomics program and perfecting protein identification processes over the past year," said Dr. Beverly Brown, vice president of business development at Linden Bioscience. "We are now pleased to offer research organizations an attractively priced and highly-personalized protein identification service that leverages leading-edge informatics systems and techniques."

About Linden Bioscience

Linden Bioscience rapidly integrates cutting-edge technology in functional genomics, proteomics, bioinformatics and computational biology into an Applied Systems Biology(TM) technology platform. The company uses this platform to discover and validate disease biomarkers, targets and therapeutics. Through its Applied Systems Biology approach, the company's vision is to - on its own and with partners - rapidly develop drugs with greater efficacy and safety as compared to those developed using traditional processes. Additional information may be found at www.lindenbioscience.com.

Strategic Proteomic Services and Applied Systems Biology are trademarks of Linden Bioscience. QSTAR is a registered trademark and TOF/TOF is a trademark of Applera Corporation or its subsidiaries in the U.S. and certain other countries. All other trademarks are the property of their respective owners.

Contact:

SunBridge Communications Bill Perkins, 617-448-5534 bperkins@sunbridgecom.com

Source: Linden Bioscience



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES